Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Laura Huppert, MD
Conference Coverage
Routine Screening for Brain Metastases Among Patients With HER2-Positive Breast Cancer
05/14/2024
Laura Huppert, MD
At Great Debates and Updates in Women’s Oncology, Laura Huppert, MD, argued that routine screening for brain metastases is unnecessary for patients with either early or metastatic HER2-positive breast cancer.
At Great Debates and Updates in Women’s Oncology, Laura Huppert, MD, argued that routine screening for brain metastases is unnecessary for patients with either early or metastatic HER2-positive breast cancer.
At Great Debates and Updates in...
05/14/2024
Oncology
Seth Wander, MD, PhD, Massachusetts General Hospital
Videos
Novel Endocrine Agents for Patients With HR-Positive Breast Cancer
05/08/2024

Featuring Seth Wander, MD, PhD

Featuring Seth Wander, MD, PhD ...
At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.
At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Ying Liu, MD, MPH
Videos
The Case for Platinum-Based Chemotherapy for Patients With Platinum-Sensitive Recurrent Ovarian Cancer
05/08/2024

Featuring Ying Liu, MD, MPH

Featuring Ying Liu, MD, MPH
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Ying Liu, MD, MPH, makes an argument for platinum-based chemotherapy as the optimal treatment for patients with platinum-sensitive recurrent ovarian cancer.
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Ying Liu, MD, MPH, makes an argument for platinum-based chemotherapy as the optimal treatment for patients with platinum-sensitive recurrent ovarian cancer.
At the 2024 Great Debates and...
05/08/2024
Oncology
Denise Yardley, MD, Sarah Cannon Research Institute
Videos
Is Age 50 Relevant for Decisions in Early HR-Positive Breast Cancer?
05/08/2024

Featuring Denise Yardley, MD

Featuring Denise Yardley, MD
At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.
At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center
Videos
Sequential Antibody Drug Conjugates for Patients With Metastatic Breast Cancer
05/08/2024

Featuring Neil Iyengar, MD

Featuring Neil Iyengar, MD
At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.
At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Bradley Monk, MD
Conference Coverage
Front-Line Treatment Options for Ovarian Cancer
12/07/2023
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates...
12/07/2023
Oncology
Colleen McCormick, MD, MPH
Videos
New and Emerging Targeted Therapies for Relapsing Ovarian Cancer
11/15/2023
At the Great Debates & Updates in Women’s Oncology meeting, Colleen McCormick, MD, MPH, gave an overview of new targeted therapies for patients with relapsing platinum-sensitive and platinum-resistant ovarian cancer.
At the Great Debates & Updates in Women’s Oncology meeting, Colleen McCormick, MD, MPH, gave an overview of new targeted therapies for patients with relapsing platinum-sensitive and platinum-resistant ovarian cancer.
At the Great Debates & Updates...
11/15/2023
Oncology
Oliver Zivanovic, MD, Memorial Sloan Kettering Cancer Center
Videos
In Support of HIPEC as Standard of Care for Stage 3 Ovarian Cancer
11/30/2022
Oliver Zivanovic, MD, defends HIPEC as standard of care treatment for patients with ovarian cancer, a topic he presented at the 2022 Great Debates and Updates in Women’s Oncology virtual meeting.
Oliver Zivanovic, MD, defends HIPEC as standard of care treatment for patients with ovarian cancer, a topic he presented at the 2022 Great Debates and Updates in Women’s Oncology virtual meeting.
Oliver Zivanovic, MD, defends...
11/30/2022
Oncology
Kathleen Moore, MD
Videos
Current and Emerging Therapies for Platinum-Resistant Ovarian Cancer
11/15/2022
Kathleen Moore, MD, gives an overview on recent developments in treatments for advanced stage ovarian cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.
Kathleen Moore, MD, gives an overview on recent developments in treatments for advanced stage ovarian cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.
Kathleen Moore, MD, gives an...
11/15/2022
Oncology
Komal Jhaveri, MD
Videos
Novel Antibody Drug Conjugates for Triple-Negative Breast Cancer
11/14/2022
Komal Jhaveri, MD, provides insights and information regarding new and emerging antibody drug conjugate therapies for patients with triple-negative breast cancer, a topic she presented at the 2022 Great Debates & Updates in Women’s Oncology...
Komal Jhaveri, MD, provides insights and information regarding new and emerging antibody drug conjugate therapies for patients with triple-negative breast cancer, a topic she presented at the 2022 Great Debates & Updates in Women’s Oncology...
Komal Jhaveri, MD, provides...
11/14/2022
Oncology

Advertisement

Advertisement

Advertisement

About

From the organizers of Great Debates & Updates, we're excited to announce a new interactive CME series connecting those treating breast and gynecologic cancers—for 2 days of interactive, expertly crafted oncology education.

Great Debates & Updates in Women's Oncology will focus on how new information fits into current community practice. Attendees will get an insightful look at more than one side of a question, giving them a chance to really engage in the discussions. These 2 conferences are sure to be an engaging, interactive educational opportunity for attendees, with several opportunities to network with both faculty and attendees.

 

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use